Study of ABSK141 for advanced solid tumors with KRAS G12D mutation
Part of Cancer clinical trials.
This study tests a new drug called ABSK141 for people with advanced solid tumors that have a specific mutation called KRAS G12D. It aims to see if the drug can shrink or control the cancer, and it has different phases for different groups of patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic cancer (solid tumor) that has been confirmed by biopsy.
- Your cancer has a specific mutation called KRAS G12D (found in certain colorectal, lung, or pancreatic cancers, or other solid tumors).
- You have not taken a KRAS G12D inhibitor or similar RAS-targeted therapy before.
- You have not had cancer that spread to your brain that is currently active.
- You are willing to follow study procedures, including possible fasting and a high-fat meal test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ABSK211 in people with advanced solid tumors that have a change in the KRAS gene. The goal is to see if the drug is safe and works against the cancer.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
This trial tests a new drug called ABSK131 in people whose cancer has a missing MTAP gene. It is for advanced solid tumors that have not responded to standard treatments.
This trial tests a new drug called ABSK112 for people with advanced non-small cell lung cancer, especially those whose cancer has a specific change in the EGFR gene (exon 20 insertion). The main goals are to see if it's safe and how the body handles it.
This trial tests a new oral drug called RNK08954 for people with advanced solid tumors that have a specific KRAS G12D genetic change. The drug targets this mutation to try to stop tumor growth. It is for patients who have already had other treatments and may not have many options left.
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
Hear when a new Solid Tumors, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.